GeoVax Labs (NASDAQ:GOVX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research report sent to investors on Monday, Benzinga reports. They currently have a $8.00 price target on the stock.

A number of other research analysts also recently issued reports on the stock. EF Hutton Acquisition Co. I upgraded shares of GeoVax Labs to a strong-buy rating in a research report on Tuesday, July 23rd. Roth Mkm began coverage on shares of GeoVax Labs in a report on Tuesday, July 16th. They set a buy rating and a $20.00 price objective on the stock. Finally, Roth Capital upgraded shares of GeoVax Labs to a strong-buy rating in a report on Tuesday, July 16th.

GeoVax Labs Trading Up 3.1 %

GeoVax Labs stock opened at $3.35 on Monday. GeoVax Labs has a 12-month low of $1.09 and a 12-month high of $9.75. The firm’s fifty day moving average is $2.40 and its 200 day moving average is $2.15.

GeoVax Labs (NASDAQ:GOVX) last released its earnings results on Tuesday, August 6th. The company reported ($1.99) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.57) by $0.58. The company had revenue of $0.30 million for the quarter. During the same quarter in the previous year, the firm earned ($3.30) EPS. As a group, equities research analysts predict that GeoVax Labs will post -7.41 EPS for the current fiscal year.

Institutional Trading of GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Armistice Capital LLC bought a new position in GeoVax Labs, Inc. (NASDAQ:GOVX) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned approximately 91.38% of GeoVax Labs at the end of the most recent reporting period. Institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.